“…Several factors mitigate the use of thrombolytics in the management of CAMI, including: the low overall mortality of patients with CAMI, the difficulty in making a reliable diagnosis, as well as a higher risk of treatment complications in this population (i.e., increased risk for cerebrovascular hemorrhage) (13,34,74,75). Some authors in this setting have advocated the use of coronary artery angioplasty, but like thrombolytic agents, its efficacy has never been proven (76). To date, the use of glycoprotein IIb/IIIa inhibitors in the setting of CAMI has not been investigated.…”